Gardasil DTC driving force behind Merck expense increase

Gardasil DTC was the chief factor behind a 21% increase in Merck marketing and administrative expenses for the fourth quarter of 2006, followed by consumer promotion of Zostavax and spending on the Januvia launch, said CEO Dick Clark in a Q4 earnings report.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions